These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 26912356)
1. Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier. Tyagi P; Kumar A; Gupta D; Singh H AAPS PharmSciTech; 2017 Jan; 18(1):156-165. PubMed ID: 26912356 [TBL] [Abstract][Full Text] [Related]
2. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation. Liu Z; Lin TM; Purro M; Xiong MP ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539 [TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator. Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959 [TBL] [Abstract][Full Text] [Related]
4. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo. Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats. Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231 [TBL] [Abstract][Full Text] [Related]
6. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo. Liu Z; Qiao J; Nagy T; Xiong MP J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889 [TBL] [Abstract][Full Text] [Related]
7. An extended-release formulation of desferrioxamine for subcutaneous administration. Toliyat T; Jorjani M; Khorasanirad Z Drug Deliv; 2009 Oct; 16(7):416-21. PubMed ID: 19640256 [TBL] [Abstract][Full Text] [Related]
8. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982 [TBL] [Abstract][Full Text] [Related]
9. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine. Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631 [TBL] [Abstract][Full Text] [Related]
10. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Bergeron RJ; Wiegand J; Brittenham GM Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795 [TBL] [Abstract][Full Text] [Related]
11. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. Farr AC; Xiong MP Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630 [TBL] [Abstract][Full Text] [Related]
12. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380 [TBL] [Abstract][Full Text] [Related]
13. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580 [TBL] [Abstract][Full Text] [Related]
14. Objectives and mechanism of iron chelation therapy. Hershko C; Link G; Konijn AM; Cabantchik ZI Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658 [TBL] [Abstract][Full Text] [Related]
15. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia. Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980 [TBL] [Abstract][Full Text] [Related]
16. Fluorene methoxycarbonyl-PEG-deferoxamine conjugates "hitchhike" with albumin in situ for iron overload therapy. Xu L; Guan R; Yu B; Li Y; Liu H; Jiang Y Int J Pharm; 2022 Sep; 625():122136. PubMed ID: 36029994 [TBL] [Abstract][Full Text] [Related]
17. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Hallaway PE; Eaton JW; Panter SS; Hedlund BE Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10108-12. PubMed ID: 2481311 [TBL] [Abstract][Full Text] [Related]
18. Composite chitosan/alginate hydrogel for controlled release of deferoxamine: A system to potentially treat iron dysregulation diseases. Rassu G; Salis A; Porcu EP; Giunchedi P; Roldo M; Gavini E Carbohydr Polym; 2016 Jan; 136():1338-47. PubMed ID: 26572479 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690 [TBL] [Abstract][Full Text] [Related]
20. HBED: A potential alternative to deferoxamine for iron-chelating therapy. Bergeron RJ; Wiegand J; Brittenham GM Blood; 1998 Feb; 91(4):1446-52. PubMed ID: 9454776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]